BRPI0813139A8 - peptídeo glp-1 com adição de cadeia oligossacarídea - Google Patents

peptídeo glp-1 com adição de cadeia oligossacarídea

Info

Publication number
BRPI0813139A8
BRPI0813139A8 BRPI0813139A BRPI0813139A BRPI0813139A8 BR PI0813139 A8 BRPI0813139 A8 BR PI0813139A8 BR PI0813139 A BRPI0813139 A BR PI0813139A BR PI0813139 A BRPI0813139 A BR PI0813139A BR PI0813139 A8 BRPI0813139 A8 BR PI0813139A8
Authority
BR
Brazil
Prior art keywords
glp
peptide
oligosaccharide chain
amino acid
chain addition
Prior art date
Application number
BRPI0813139A
Other languages
English (en)
Inventor
Asai Hiroaki
Sakamoto Izumi
Tezuka Katsunari
Fukae Kazuhiro
Tsuji Takashi
Kajihara Yasuhiro
Nambu Yuri
Original Assignee
Glytech Inc
Otsuka Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc, Otsuka Chemical Co Ltd filed Critical Glytech Inc
Publication of BRPI0813139A2 publication Critical patent/BRPI0813139A2/pt
Publication of BRPI0813139A8 publication Critical patent/BRPI0813139A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

peptídeo glp-1 com adição de cadeia oligossacarídea a presente invenção relaciona-se a um peptídeo glp-1 com adição de cadeia oligossacarídea que tem maior estabilidade no sangue que aquela de glp-1 e, preferivelmente, exibe maior atividade de controle de níveis sanguíneos de açúcar que aquela de glp-1. a presente invenção relaciona-se a um peptídeo glp-1 com adição de cadeia oligossacarídea que tem atividade de glp-1, em que pelo menos um aminoácido é substituído com um aminoácido com adição de cadeia oligossacarídea, in: (a) glp-1; (b) um peptídeo que tem a sequência de aminoácidos de glp-1 com deleção, substituição ou adição de um ou vários aminoácidos; ou (c) um análogo de glp-1.
BRPI0813139A 2007-06-19 2008-06-17 peptídeo glp-1 com adição de cadeia oligossacarídea BRPI0813139A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160951 2007-06-19
PCT/JP2008/001554 WO2008155900A1 (ja) 2007-06-19 2008-06-17 糖鎖付加glp-1ペプチド

Publications (2)

Publication Number Publication Date
BRPI0813139A2 BRPI0813139A2 (pt) 2015-02-18
BRPI0813139A8 true BRPI0813139A8 (pt) 2019-01-29

Family

ID=40156064

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813139A BRPI0813139A8 (pt) 2007-06-19 2008-06-17 peptídeo glp-1 com adição de cadeia oligossacarídea

Country Status (13)

Country Link
US (3) US7985731B2 (pt)
EP (1) EP2172479B1 (pt)
JP (1) JP5646848B2 (pt)
KR (1) KR20100049032A (pt)
CN (1) CN102015761A (pt)
AU (1) AU2008264750C1 (pt)
BR (1) BRPI0813139A8 (pt)
CA (1) CA2696615A1 (pt)
DK (1) DK2172479T3 (pt)
RU (1) RU2539829C2 (pt)
SG (1) SG178797A1 (pt)
TW (1) TWI423821B (pt)
WO (1) WO2008155900A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008264750C1 (en) * 2007-06-19 2013-01-10 Glytech, Inc. GLP-1 peptide having sugar chain attached thereto
AU2009261441B2 (en) * 2008-06-17 2013-01-10 Glytech, Inc. Oligosaccharide chain added glp-1 peptide
US20120264684A1 (en) * 2009-10-30 2012-10-18 Yasuhiro Kajihara Glycosylated Form of Antigenic GLP-1 Analogue
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
EP2657244B8 (en) * 2010-12-22 2016-08-31 Ajinomoto Co., Inc. Glycoside compounds as glp-1 secretion promoting agents
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2013032011A1 (ja) * 2011-09-04 2013-03-07 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US10358470B2 (en) 2011-10-01 2019-07-23 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
KR102227918B1 (ko) * 2012-11-22 2021-03-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 링커, 당쇄 부가 링커 부분과 생리 활성 물질 부분을 함유하는 화합물 또는 그의 염, 및 이들의 제조 방법
WO2014084110A1 (ja) * 2012-11-30 2014-06-05 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
DK2982686T3 (en) * 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
MX2017016845A (es) 2015-06-30 2018-08-01 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
CN108699125B (zh) 2015-12-31 2022-10-28 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
UA126662C2 (uk) 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
CA3147770A1 (en) * 2019-08-13 2021-02-18 Jae Ha Ryu Exenatide analog and use thereof
EP4104849A4 (en) * 2020-01-13 2024-03-27 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A LONG-ACTING CONJUGATE OF A TRIPLE AGONIST WITH ACTIVITY RELATED TO GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE
CN115463208B (zh) * 2021-10-09 2023-05-30 上海海赜生物科技有限公司 一种口服降糖组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943763B2 (en) * 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1605897T1 (sl) 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
CN1802386B (zh) * 2003-06-12 2010-12-15 伊莱利利公司 Glp-1类似物融合蛋白质
KR100731875B1 (ko) * 2003-07-28 2007-06-25 오츠카 가가쿠 가부시키가이샤 아미노화 복합형 당사슬 유도체 및 그의 제조방법
JP2005095331A (ja) 2003-09-24 2005-04-14 Ihara Suisan Kk 魚皮真皮コラーゲンを含有する発泡体シートおよびその用途
WO2006010143A2 (en) * 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
JPWO2007063907A1 (ja) 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
AU2008264750C1 (en) * 2007-06-19 2013-01-10 Glytech, Inc. GLP-1 peptide having sugar chain attached thereto

Also Published As

Publication number Publication date
EP2172479B1 (en) 2016-09-14
AU2008264750C1 (en) 2013-01-10
RU2010101331A (ru) 2011-07-27
SG178797A1 (en) 2012-03-29
CN102015761A (zh) 2011-04-13
DK2172479T3 (en) 2016-12-19
CA2696615A1 (en) 2008-12-24
AU2008264750A1 (en) 2008-12-24
JP5646848B2 (ja) 2014-12-24
US20090111739A1 (en) 2009-04-30
RU2539829C2 (ru) 2015-01-27
EP2172479A4 (en) 2011-08-24
US20130345129A1 (en) 2013-12-26
US8507429B2 (en) 2013-08-13
US20110245166A1 (en) 2011-10-06
WO2008155900A1 (ja) 2008-12-24
TWI423821B (zh) 2014-01-21
BRPI0813139A2 (pt) 2015-02-18
KR20100049032A (ko) 2010-05-11
JPWO2008155900A1 (ja) 2010-08-26
TW200902068A (en) 2009-01-16
US7985731B2 (en) 2011-07-26
AU2008264750B2 (en) 2012-07-05
EP2172479A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
BRPI0813139A8 (pt) peptídeo glp-1 com adição de cadeia oligossacarídea
BR112013010487A2 (pt) novos substratos de coelenterazina e métodos de uso
BRPI0717183B8 (pt) exendina ou análogo de exendina modificada por peg, composição e seu uso
ATE498631T1 (de) Glucagon-like-peptide-2- (glp-2-) analoga
BR112018076693A2 (pt) análogos de urocortina-2 modificados por ácido graxo, para o tratamento de diabetes e doença renal crônica
BR112016017534A2 (pt) proteína
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
HK1134283A1 (en) Arylsulfonamide compounds
BR112014009790A2 (pt) composto para modulação antisense da expressão de gccr, seu uso e composição
BR112014027283A2 (pt) variantes de enzima aprimoradas
BRPI0604538A (pt) produtos de cereal de conteúdo de umidade elevado com vida útil elevada
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MY138708A (en) Biaryloxymethylarenecarboxylic acids
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
BR112015001601A2 (pt) células de levedura tendo curso de tca redutor de piruvato em succinato e superexpressão de uma enzima transidrogenase nad(p)+ exógena
BR112014009225A8 (pt) uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes
DE602007014210D1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
BR112015020692A2 (pt) variantes de alfa-amilase
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
BR112012014681A2 (pt) Uso de cry1da em combinação com cry1ca para gerenciamento de insetos resistentes
BR112013011076A2 (pt) composição compreendendo um peptídeo e um inibidor da neuraminidase viral
BR112018006724A2 (pt) ácido caurenoico hidroxilases
ATE406903T1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
BRPI0823018A2 (pt) polinucleotídeo, proteína codificada pelo polinucleotídeo, vetor, transformante, métodos para produzir a proteína e para produzir um conjugado glicuronídeo.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GLYTECH, INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL